Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin-related modifier 1 (URM1) is a highly conserved ubiquitin-like protein present from yeast to humans, characterized structurally by a β-grasp fold[1][8]. Functionally, URM1 has a dual role: (1) as a protein modifier, it forms covalent conjugates with other proteins in a process termed urmylation—an atypical post-translational modification that is often triggered by oxidative stress and facilitated by its activating enzyme, Uba4 (or MOCS3 in humans)[1][2][4][5][7]. Unlike traditional ubiquitin or other ubiquitin-like pathways, URM1 conjugation is independent of E2/E3 enzymes and is linked to direct redox regulation and cysteine persulfidation[4][5]. (2) As a sulfur carrier protein for tRNA thiolation, URM1 delivers sulfur to specific tRNAs, which is essential for modifying the wobble uridine of tRNA anticodons via the Ncs2-Ncs6 sulfur–transferase complex, optimizing translational efficiency and cellular stress responses[5][6][7]. Loss of URM1-dependent tRNA modifications is associated with broad cellular dysfunction, with links to cancer and neurodegenerative diseases through defective protein translation and stress adaptation[5]. No direct small molecule drugs, clinical biomarkers, or safety concerns are currently identified for URM1, and it is not considered a classical therapeutic target such as an enzyme, receptor, or transporter[1][5][6][7]. URM1 is mainly of interest in fundamental cell biology and evolutionary studies of ubiquitin-like protein modification systems. Key facts: - URM1 is both a post-translational modifier (urmylation substrate conjugator) and a sulfur transfer protein for tRNA modification[1][2][3][5][6][7]. - URM1-mediated sulfur transfer and urmylation are integral to translation and oxidative stress adaptation, but not directly targeted by drugs or established as direct therapeutic targets at present[1][5][6][7]. - Disease links arise from loss of its tRNA modification function—not from targeting the protein directly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin-related modifier 1 (URM1).